FroggaBio Inc

www.froggabio.com

FroggaBio is a distributor of laboratory products, supply instruments, reagents and disposables. We serve customers within academic and industrial research institutes, biotechnology and pharmaceutical companies and hospitals. Headquartered in Toronto Canada, FroggaBio represents numerous companies exclusively allowing us to offer a comprehensive line of products in biological, chemical, and diagnostic fields at very competitive prices.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

news image

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More

Research, Industry Outlook

BIGHAT BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH MERCK

BigHat Biosciences, Inc. | November 30, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better...

Read More

Industrial Impact

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

news image

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More

Cell and Gene Therapy

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More
news image

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More
news image

Research, Industry Outlook

BIGHAT BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH MERCK

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better...

Read More
news image

Industrial Impact

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More
news image

Cell and Gene Therapy

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us